[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370940-105":59,"doc-detail-370940-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","therapeutic-targeting-of-protein-lysine-and-arginine-methyltransferases-principles-and-strategies-for-inhibitor-design","Therapeutic Targeting of Protein Lysine and Arginine Methyltransferases: Principles and Strategies for Inhibitor Design","","Standard cancer chemotherapy is increasingly supplemented with novel therapies to overcome recurring chemoresistance pathways. Resistance is widespread across tumour types and can be driven by protein methylation, a post-translational modification controlled by protein methyltransferases (PMTs) that regulate protein activity through methylation of lysine and arginine residues. Dysregulated lysine and arginine methyltransferases are linked to progression and drug resistance, prompting small-molecule PMT inhibitor development, yet many candidates fail in later efficacy or safety phases, motivating improved inhibitor design. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/therapeutic-targeting-of-protein-lysine-and-arginine-methyltransferases-principles-and-strategies-for-inhibitor-design/370940/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/therapeutic-targeting-of-protein-lysine-and-arginine-methyltransferases-principles-and-strategies-for-inhibitor-design/370940.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are protein methyltransferases considered therapeutic targets in cancer?","Question",{"text":112,"@type":113},"Protein lysine and arginine methyltransferases (PKMTs and PRMTs) regulate protein function through methylation. Dysregulation of these PMTs is linked to cancer progression and drug resistance, making them attractive targets for therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limits the clinical success of PMT inhibitors?",{"text":117,"@type":113},"Although many small-molecule PMT inhibitors show promise in preclinical studies, numerous candidates fail to demonstrate sufficient efficacy or safety in later clinical stages. This gap highlights the need to improve inhibitor design approaches.",{"name":119,"@type":110,"acceptedAnswer":120},"What must be understood to design more selective and potent PMT inhibitors?",{"text":121,"@type":113},"Effective design requires a deeper understanding of PMT mechanisms, catalytic domains, and their roles in chemoresistance pathways. Mechanistic insights support strategies to develop next-generation inhibitors for improved therapeutic potential.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370940,1791222487,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review  \nTherapeutic Targeting of Protein Lysine and Arginine Methyltransferases: Principles and Strategies for Inhibitor Design  \nIsaac Micallef 1,2 and Byron Baron 2, *  \nAcademic Editor: Zhongzhou Chen  \nReceived: 4 August 2025  \nRevised: 12 September 2025  \nAccepted: 15 September 2025  \nPublished: 17 September 2025  \nCitation: Micallef, I.; Baron, B. Therapeutic Targeting of Protein Lysine and Arginine Methyltransferases: Principles and Strategies for Inhibitor Design. Int. J. Mol. Sci. 2025, 26, 9038 . [https://doi.org/10.3390/ijms26189038](https://doi.org/10.3390/ijms26189038)  \n[Copyright:](Copyright:) © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Tumor Genetics and Biology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan; [isaac.micallef.17@um.edu.mt](isaac.micallef.17@um.edu.mt)  \n2 Centre for Molecular Medicine and Biobanking, University of Malta, MSD 2080 Msida, Malta  \n* [Correspondence: byron.baron@um.edu.mt](Correspondence: byron.baron@um.edu.mt)  \nAbstract  \nStandard cancer chemotherapy is increasingly being supplemented with novel therapeutics to overcome known chemoresistance pathways. Resistance to treatment is common across various tumour types, driven by multiple mechanisms. One emerging contributor is protein methylation, a post-translational modification mediated by protein methyltransferases (PMTs), which regulate protein function by adding methyl groups, mainly onlysine and arginine residues. Dysregulation of protein lysine methyltransferases (PKMTs) and protein arginine methyltransferases (PRMTs) has been linked to cancer progression and drug resistance, making them attractive therapeutic targets. Consequently, several small-molecule PMT inhibitors have been developed, with some progressing to clinical trials. However, many candidates showing promise in preclinical studies fail to demonstrate efficacy or safety in later stages, limiting clinical success. This gap highlights the need to rethink current approaches to PMT inhibitor design. A deeper understanding of PMT mechanisms, catalytic domains, and their roles in chemoresistance is essential for creating more selective, potent, and clinically viable inhibitors. This review will summarise major chemoresistance pathways and PMTs implicated in cancer, then explore current and prospective PMT inhibitor classes. Building on mechanistic insights, we propose strategies to develop next-generation inhibitors with improved therapeutic potential against chemoresistant cancers.  \nKeywords: protein methylation; protein methyltransferases (PMTs); PMT inhibitors; methylproteomics; chemoresistance  \n1. Introduction  \n1.1. Challenge to Treatment  \nChemoresistance is recognised as the greatest challenge in the successful treatment of cancer by chemotherapy, with the development and proliferation of highly aggressive phenotypes resulting in an associated poor prognosis.  \nGiven the well-documented impact of methylation on protein expression levels through its action on histones, it is no surprise that protein methyltransferase (PMT) inhibitors have been considered as potential therapeutics to prevent or counter specific chemoresistance mechanisms, at least in a subset of patients, in the hopes of increasing the possibility of obtaining long-term benefits with the currently administered chemotherapeutic regimens. However, despite this knowledge related to histones, there is at present a lack  \nof understanding as to the biological relevance of non-histone proteins targeted by PMTsas part of chemoresistance mechanisms.  \nThe greatest stumbling block presently is that the functional role played by PMTsin either the deve","cbCaipRViKH0RKDc","https://ap.wps.com/l/cbCaipRViKH0RKDc","pdf",658966,26,"English","# Abstract\n# Introduction\n## Challenge to Treatment\n## Chemoresistance Mechanisms","[{\"question\":\"Why are protein methyltransferases considered therapeutic targets in cancer?\",\"answer\":\"Protein lysine and arginine methyltransferases (PKMTs and PRMTs) regulate protein function through methylation. Dysregulation of these PMTs is linked to cancer progression and drug resistance, making them attractive targets for therapy.\"},{\"question\":\"What limits the clinical success of PMT inhibitors?\",\"answer\":\"Although many small-molecule PMT inhibitors show promise in preclinical studies, numerous candidates fail to demonstrate sufficient efficacy or safety in later clinical stages. This gap highlights the need to improve inhibitor design approaches.\"},{\"question\":\"What must be understood to design more selective and potent PMT inhibitors?\",\"answer\":\"Effective design requires a deeper understanding of PMT mechanisms, catalytic domains, and their roles in chemoresistance pathways. Mechanistic insights support strategies to develop next-generation inhibitors for improved therapeutic potential.\"}]","Therapeutic Targeting of Protein Lysine and Arginine Methyltransferases: Principles and Strategies for Inhibitor Design | PDF",1790190870,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/005c6c3b77430a838a376b2cd1a1a839.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/543eafa4068d89614709f1568747a41a.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f668fba5dff7c5092a63eb56172c6149.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f3d173258bf94b4e83c39c8419f27f6.webp",980,1385]